MMSC 433 Exam 3 questions with |\ |\ |\ |\ |\ |\
answers
chronic myeloid leukemia (CML) chromosomal abnormality -
|\ |\ |\ |\ |\ |\ |\
CORRECT ANSWERS ✔✔Philadelphia chromosome (~95% of
|\ |\ |\ |\ |\ |\
cases)
polycythemia vera (PV) chromosomal abnormality - CORRECT
|\ |\ |\ |\ |\ |\ |\
ANSWERS ✔✔JAK2V617F mutation (most cases)
|\ |\ |\ |\
chronic myeloproliferative disorders - CORRECT ANSWERS ✔✔-
|\ |\ |\ |\ |\ |\
chronic myeloid leukemia (CML)
|\ |\ |\
-polycythemia vera (PV) |\ |\
-essential thrombocythemia (ET)
|\ |\
-primary myelofibrosis (PMF)
|\ |\
-chronic neutrophilic leukemia (CNL)
|\ |\ |\
-chronic myelomonocytic leukemia (CMML)
|\ |\ |\
-juvenile myelomonocytic leukemia (JMML)
|\ |\ |\
polycythemia vera major criteria (WHO) - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\ |\ |\
✔✔-hemoglobin >16.5 g/dL (men), >16 g/dL (women) |\ |\ |\ |\ |\ |\
-Hct >49% (men), >48% (women)
|\ |\ |\ |\
-increased RCM >35 mL/kg (men), >31 mL/kg (women)
|\ |\ |\ |\ |\ |\ |\
-BM biopsy with hypercellularity and panmyelosis
|\ |\ |\ |\ |\
-presence of JAK2V617F or JAK2 Exon 12 mutations
|\ |\ |\ |\ |\ |\ |\
, polycythemia vera minor criteria (WHO) - CORRECT ANSWERS |\ |\ |\ |\ |\ |\ |\ |\
✔✔subnormal serum EPO levels |\ |\ |\
chronic myeloid leukemia (CML) - CORRECT ANSWERS ✔✔-
|\ |\ |\ |\ |\ |\ |\
etiology: a single genetic translocation in a pluripotent
|\ |\ |\ |\ |\ |\ |\ |\
hematopoietic stem cell causes clonal overproduction of |\ |\ |\ |\ |\ |\ |\
immature neutrophils, usually diagnosed between age 45-55
|\ |\ |\ |\ |\ |\
-chromosomal abnormality: Philadelphia chromosome |\ |\ |\
-morphology: myeloblasts, promyelovytes, bands, segmented |\ |\ |\ |\ |\
neutrophils (all stages of neutrophil development) seen in the
|\ |\ |\ |\ |\ |\ |\ |\ |\
peripheral blood, nRBCs present, *gaucher-like macrophages
|\ |\ |\ |\ |\ |\
present*, very small megakaryocytes present
|\ |\ |\ |\
-symptoms: infections with Strep pneumoniae, anemia, bleeding,
|\ |\ |\ |\ |\ |\ |\
splenomegaly
-PB: RBCs normal to inc, retics normal, total WBCs increased,
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
granulocytes increased (neutrophils, basophils, eosinophils), PLTs
|\ |\ |\ |\ |\ |\
normal to inc, *LAP stain decreased*
|\ |\ |\ |\ |\
-BM: hypercellular, increased granulopoiesis, decreased
|\ |\ |\ |\ |\
erythropoiesis, megakaryopoiesis increased, reticulin fibers |\ |\ |\ |\ |\
increased
chronic myeloid leukemia (CML) stages - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\ |\ |\
✔✔chronic phase (3-4 years) → accelerated phase → blastic
|\ |\ |\ |\ |\ |\ |\ |\ |\
phase → possible transition to acute leukemia (poor prognosis)
|\ |\ |\ |\ |\ |\ |\ |\
chronic myeloid leukemia (CML) treatments - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\ |\
✔✔-BM transplant or SCT= CURE
|\ |\ |\ |\ |\
-*gleevec* (imatnib mesylate) |\ |\ |\
answers
chronic myeloid leukemia (CML) chromosomal abnormality -
|\ |\ |\ |\ |\ |\ |\
CORRECT ANSWERS ✔✔Philadelphia chromosome (~95% of
|\ |\ |\ |\ |\ |\
cases)
polycythemia vera (PV) chromosomal abnormality - CORRECT
|\ |\ |\ |\ |\ |\ |\
ANSWERS ✔✔JAK2V617F mutation (most cases)
|\ |\ |\ |\
chronic myeloproliferative disorders - CORRECT ANSWERS ✔✔-
|\ |\ |\ |\ |\ |\
chronic myeloid leukemia (CML)
|\ |\ |\
-polycythemia vera (PV) |\ |\
-essential thrombocythemia (ET)
|\ |\
-primary myelofibrosis (PMF)
|\ |\
-chronic neutrophilic leukemia (CNL)
|\ |\ |\
-chronic myelomonocytic leukemia (CMML)
|\ |\ |\
-juvenile myelomonocytic leukemia (JMML)
|\ |\ |\
polycythemia vera major criteria (WHO) - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\ |\ |\
✔✔-hemoglobin >16.5 g/dL (men), >16 g/dL (women) |\ |\ |\ |\ |\ |\
-Hct >49% (men), >48% (women)
|\ |\ |\ |\
-increased RCM >35 mL/kg (men), >31 mL/kg (women)
|\ |\ |\ |\ |\ |\ |\
-BM biopsy with hypercellularity and panmyelosis
|\ |\ |\ |\ |\
-presence of JAK2V617F or JAK2 Exon 12 mutations
|\ |\ |\ |\ |\ |\ |\
, polycythemia vera minor criteria (WHO) - CORRECT ANSWERS |\ |\ |\ |\ |\ |\ |\ |\
✔✔subnormal serum EPO levels |\ |\ |\
chronic myeloid leukemia (CML) - CORRECT ANSWERS ✔✔-
|\ |\ |\ |\ |\ |\ |\
etiology: a single genetic translocation in a pluripotent
|\ |\ |\ |\ |\ |\ |\ |\
hematopoietic stem cell causes clonal overproduction of |\ |\ |\ |\ |\ |\ |\
immature neutrophils, usually diagnosed between age 45-55
|\ |\ |\ |\ |\ |\
-chromosomal abnormality: Philadelphia chromosome |\ |\ |\
-morphology: myeloblasts, promyelovytes, bands, segmented |\ |\ |\ |\ |\
neutrophils (all stages of neutrophil development) seen in the
|\ |\ |\ |\ |\ |\ |\ |\ |\
peripheral blood, nRBCs present, *gaucher-like macrophages
|\ |\ |\ |\ |\ |\
present*, very small megakaryocytes present
|\ |\ |\ |\
-symptoms: infections with Strep pneumoniae, anemia, bleeding,
|\ |\ |\ |\ |\ |\ |\
splenomegaly
-PB: RBCs normal to inc, retics normal, total WBCs increased,
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
granulocytes increased (neutrophils, basophils, eosinophils), PLTs
|\ |\ |\ |\ |\ |\
normal to inc, *LAP stain decreased*
|\ |\ |\ |\ |\
-BM: hypercellular, increased granulopoiesis, decreased
|\ |\ |\ |\ |\
erythropoiesis, megakaryopoiesis increased, reticulin fibers |\ |\ |\ |\ |\
increased
chronic myeloid leukemia (CML) stages - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\ |\ |\
✔✔chronic phase (3-4 years) → accelerated phase → blastic
|\ |\ |\ |\ |\ |\ |\ |\ |\
phase → possible transition to acute leukemia (poor prognosis)
|\ |\ |\ |\ |\ |\ |\ |\
chronic myeloid leukemia (CML) treatments - CORRECT ANSWERS
|\ |\ |\ |\ |\ |\ |\
✔✔-BM transplant or SCT= CURE
|\ |\ |\ |\ |\
-*gleevec* (imatnib mesylate) |\ |\ |\
